New β-glucan inhibitors as antifungal drugs

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 10, 2011, Pages 1597-1610

  Hector, Richard F ^a   Bierer, Donald E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAYER PHARMA AG   (Germany)

Author keywords

glucan; Antifungal; Aspergillosis; Aspergillus; Candida; Candidiasis; Echinocandin; Enfumafungin

Indexed keywords

ANILINE DERIVATIVE; ANTIFUNGAL AGENT; BETA GLUCAN; BETA GLUCAN INHIBITOR; CASPOFUNGIN; ECHINOCANDIN; ECHINOCANDIN B; ECHINOCANDIN B DERIVATIVE; ENFUMAFUNGIN; ENFUMAFUNGIN DERIVATIVE; ITRACONAZOLE; L 733560; MK 3118; PAPULACANDIN B; PYRIDAZINONE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ALKYLATION; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SYNTHESIS; INVASIVE ASPERGILLOSIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW; SCHIZOSACCHAROMYCES POMBE; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; BETA-GLUCANS; BIOLOGICAL AVAILABILITY; DRUG DESIGN; GLYCOSIDES; HUMANS; MYCOSES; PATENTS AS TOPIC; TRITERPENES;

EID: 80053023504     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.603899     Document Type: Review

References (56)

1. Lesage G, Bussey H. Cell wall assembly in Saccharomyces cerevisiae. Microbiol Mol Biol Rev 2006;70:317-43 (Pubitemid 43895030)
2. Klis FM, Boorsma A, De Groot PW. Cell wall construction in Saccharomyces cerevisiae. Yeast 2006;23:185-202
3. Duran A, Perez P. Cell wall synthesis. In: Egel R. editor. Molecular biology of Schizosaccharomyces pombe. Genetics, genomics and beyond. Springer Verlag; Berlin; 2004. p. 269-79
4. Hector RF. Compounds active against the cell wall of medically important fungi. Clin Microbiol Rev 1993;6:1-21 (Pubitemid 23055191)
5. Pettengell K, Mynhardt J, Kluyts T, et al. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004;20(4):475-81 (Pubitemid 39120260)
6. Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004;36(5):372-9 (Pubitemid 38967695)
7. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis 2008;46(3):327-60 (Pubitemid 351265310)
8. Basilea Pharmaceutica AG. Cyclic compounds. US6489440; 2002
9. Basilea Pharmaceutica AG. Aerothricin derivatives. US6849709; 2005
10. HMV Corp. Cyclic lipopeptide from Cryptosporiopsis quercina possessing antifungal activity. US6613738; 2003
11. Merck & Co. Antifungal fermentation product. US4931352; 1990
12. Merck & Co. Process for antifungal fermentation product. US4968608; 1990
13. Merck & Co. Phosphorylated cyclic lipopeptide. US5198421; 1993
14. Merck & Co. Lipopeptide derivatives. US5330973; 1994
15. Fujisawa Pharmaceutical Co., Ltd. (Astellas). Polypeptide compound and a process for preparation thereof. US5569646; 1996
16. Fujisawa Pharmaceutical Co., Ltd (Astellas). Echinocandine derivatives with antimicrobial activity. US6331521; 2001
17. Eli Lilly & Co. Cyclic peptide antifungal agents and process for preparation thereof. US6384013; 2002
18. Eli Lilly & Co. Cyclic peptide antifungal agents and process for preparation thereof. US6916784; 2005
19. Eli Lilly & Co. Cyclic peptide antifungal agents and process for preparation thereof. US6743777; 2004
20. Eli Lilly & Co. Cyclic peptide antifungal agents and process for preparation thereof. US7790744; 2010
21. Krishnarao TV, Galgiani JN. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 1997;41(9):1957-60 (Pubitemid 27383236)
22. Zhanel GG, Karlowsky JA, Harding GA, Balko TV. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother 1997;41(4):863-5 (Pubitemid 27150550)
23. Schwartz RE, Smith SK, Onishi JC, et al. Isolation and structural determination of enfumafungin, a triterpene glycoside antifungal agent that is a specific inhibitor of glucan synthesis. J Am Chem Soc 2000;122:4882-6 (Pubitemid 30347028)
24. Merck & Co., Scynexis, Inc. Antifungal agents. WO2009045311; 2009
25. Merck & Co., Scynexis, Inc. Antifungal agents. WO2010019204; 2010
26. Merck & Co., Scynexis, Inc. Antifungal agents. US20100113439; 2010
27. Liberator P, Giacobbe R, Racine F, et al. Semi-synthetic analogs of enfumafungin: novel inhibitors of B-1,2-glucan synthase (GS) with potent in vitro antifungal activity [abstract F1-847]. Proceedings of the 50th Interscience Cong. Antimicrob. Agents Chemother. 50th ICAAC, Boston, MA, 2010
28. Merck & Co., Scynexis, Inc. Antifungal agents. WO2010019206; 2010
29. Merck & Co. Antifungal agent obtained from hormonema. US5756472; 1998
30. Merck & Co. Antifungal agent. EP0877618B; 2003
31. Onishi J, Meinz M, Thompson J, et al. Discovery of novel antifungal (1,3)-beta- D-glucan synthase inhibitors. Antimicrob Agents Chemother 2000;44:368-77 (Pubitemid 30060733)
32. Pelaez F, Cabello A, Platas G, et al. The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms. Syst Appl Microbiol 2000;23(3):333-43
33. Reese AJ, Yoneda A, Breger JA, et al. Loss of cell wall alpha(1-3) glucan affects Cryptococcus neoformans from ultrastructure to virulence. Mol Microbiol 2007;63(5):1385-98
34. Martins IM, Cortes JC, Munoz J, et al. Differential activities of three families of specific beta(1,3)glucan synthase inhibitors in wild-type and resistant strains of fission yeast. J Biol Chem 2011;286(5):3484-96
35. Balkovej J, Bouffard JA, Dropkinski JF, et al. Derivatives of the beta-1,3-glucan synthase (GS) inhibitor enfumafungin with potent antifungal activity - Initial studies [abstract F1-849]. Proceedings of the 49th Interscience Cong. Antimicrob. Agents Chemother. 49th ICAAC, San Francisco, CA, 2009
36. Motyl M, Tan C, Liberator P, et al. MK-3118, an orally active enfumafungin with potent in vitro anti-fungal activity [abstract F1-847]. Proceedings of the 50th Interscience Cong. Antimicrob. Agents Chemother. 50th ICAAC, Boston, MA, 2010
37. Trucksis M, Garrett G, Heirman I, et al. A phase I single rising dose study evaluating the safety, tolerability and pharmacokinetics of an oral glucan synthase inhibitor in healthy male volunteers [abstract F1-1975]. Proceedings of the 50th Interscience Cong. Antimicrob. Agents Chemother. 50th ICAAC, Boston, MA, 2010
38. Flaherty A, Abruzzo G, Gill C, et al. Evaluation of enfumafungin derivative MK-3118 in two mouse models of disseminated aspergillosis [abstract F1- 849]. Proceedings of the 50th Interscience Cong. Antimicrob. Agents Chemother, Boston, MA, 2010
39. Schering Corp. and Albany Molecular Research, Inc. Pyridazinone derivatives useful as glucan synthase inhibitors. US20090170861; 2009
40. Schering Corp. Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors. US20100158992; 2010
41. Aventis Pharma Deutschland GMBH. Cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical. US7166572; 2007
42. Aventis Pharma SA. Echinocandin derivatives, their method of preparation and their application as anti-fungal agents. US7160983; 2007
43. Aventis Pharma SA. Echinocandin derivatives, preparation method and application as anti-fungal agents. US6677429; 2004
44. Aventis Pharma SA. Derivatives of echinocandine, their preparation process and their use as antifungals. US7192920; 2007
45. Aventis Pharma SA. Echinocandin derivatives, method for preparing same and application as antifungal agents. US7022669; 2006
46. Aventis Pharma SA. Echinocandin derivatives, their method of preparation and their application as anti-fungal agents. US7285619; 2007
47. Gopal PK, Shepherd MG, Sullivan PA. Analysis of wall glucans from yeast, hyphal and germ-tube forming cells of Candida albicans. J Gen Microbiol 1984;130:3295-301 (Pubitemid 15160213)
48. Herrero AB, Magnelli P, Mansour MK, et al. KRE5 gene null mutant strains of Candida albicans are avirulent and have altered cell wall composition and hypha formation properties. Eukaryot Cell 2004;3:1423-32 (Pubitemid 40025101)
49. Umeyama T, Kaneko A, Watanabe H, et al. Deletion of the CaBIG1 gene reduces beta-1,6-glucan synthesis, filamentation, adhesion, and virulence in Candida albicans. Infect Immun 2006;74:2373-81
50. Daiichi Sankyo Co., Ltd. Antifungal bicyclic hetero ring compounds. US7737166; 2010
51. Kuroyanagi J, Kanai K, Sugimoto Y, et al. Novel antifungal agents: Triazolopyridines as inhibitors of beta-1,6-glucan synthesis. J Bioorg Med Chem 2010;18:5845-54
52. Kuroyanagi J, Kanai K, Sugimoto Y, et al. 1,3-Benzoxazole-4-carbonitrile as a novel antifungal scaffold of beta-1,6-glucan synthesis inhibitors. J Bioorg Med Chem 2010;18:7593-606
53. Takeshita H, Watanabe J, Kimura Y, et al. Novel pyridobenzimidazole derivatives exhibiting antifungal activity by the inhibition of beta-1,6-glucan synthesis. J Bioorg Med Chem 2010;20:3893-6
54. Kitamura A. Discovery and characterization of beta-1,6-glucan inhibitors. Expert Opin Drug Discov 2010;5(8):739-49
55. UCB Pharma, S.A. Substituted aniline derivatives. WO2008012524; 2008
56. UCB Pharma, S.A. Substituted aniline derivatives. US7678785; 2010